US › Healthcare

Abeona Therapeutics Inc (ABEO)

US · Healthcare · Biotechnology

$6.82+6.73%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$8.7M
Net profit
$-17.1M
Profit YoY
-41.9%
EPS
$-0.30
EPS estimate
$-0.39
Net margin
-195.8%

EPS came in at -0.30 against a street estimate of -0.39 — a beat of 23.1%.

Key statistics

Market cap
$365.9M
P/E
6.8
Forward P/E
526.3
P/B
2.52
Book value
$2.55
EPS (TTM)
$0.95
52-week high
$7.54
52-week low
$4.00
50-day MA
$6.04
200-day MA
$5.32
Beta
1.33

Analyst view

Analysts rate Abeona Therapeutics Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $19.71.

Shareholding

Insiders
16.54%
Institutions
70.48%

Largest institutional holders

FundStake
Nantahala Capital Management, LLC8.80%
BlackRock Inc5.61%
AIGH Capital Management, LLC5.44%
Cable Car Capital LLC5.28%
Suvretta Capital Management, LLC4.70%
Vanguard Capital Management, LLC3.80%
Propel Bio Management LLC2.33%
Kennedy Capital Management Inc2.22%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Abeona Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.